Quality of life outcomes after isolated limb infusion

Annals of Surgical Oncology

Volumn 19, Issue 5, 2012, Pages 1373-1378

  McClaine, Rebecca J ^a   Giglia, Joseph S ^a   Ahmad, Syed A ^a   McCoy, Stephanie J ^a   Sussman, Jeffrey J ^a,b  

^a UNIVERSITY OF CINCINNATI   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DACTINOMYCIN; HEPARIN; INTERFERON; MELPHALAN; PAPAVERINE;

AGED; ARTICLE; BANDAGE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER THERAPY; CATHETER; CLINICAL ARTICLE; EXCISION; FASCIOTOMY; FEMALE; HUMAN; HYPERTHERMIA; ISOLATED LIMB INFUSION; LIMB INFUSION THERAPY; LYMPH NODE DISSECTION; MALE; MELANOMA; MERKEL CELL TUMOR; OUTCOME ASSESSMENT; OVERALL SURVIVAL; QUALITY OF LIFE; QUESTIONNAIRE; SENTINEL LYMPH NODE; TREATMENT RESPONSE;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARM; CARCINOMA, MERKEL CELL; CROSS-SECTIONAL STUDIES; DACTINOMYCIN; EDEMA; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPESTHESIA; INFUSIONS, INTRAVENOUS; LEG; LENGTH OF STAY; MALE; MELANOMA; MELPHALAN; NEOPLASM RECURRENCE, LOCAL; QUALITY OF LIFE; SKIN NEOPLASMS; SURVIVAL RATE;

EID: 84862547419     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-012-2239-0     Document Type: Article

References (13)

1. Creech O Jr, Krementz ET, Ryan RF, et al. Chemotherapy of cancer: regional perfusion ultilizing an extracorporeal circuit. Ann Surg. 1958;148:616-32.
2. Thompson JF, Kam PC, Waugh RC, Harman CR. Isolated limb infusion with cytotoxic agents: a simple alternative to isolated limb perfusion. Semin Surg Oncol. 1998;14:238-47. (Pubitemid 28146516)
3. Beasley GM, Peterson RP, Yoo J, et al. Isolated limb infusion for in-transit malignant melanoma of the extremity: a well tolerated but less effective alternative to hyperthermic isolated limb perfusion. Ann Surg Oncol. 2008;15:2195-205.
4. Brady MS, Brown K, Patel A, et al. A phase II trial of isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft tissue sarcoma of the extremity. Ann Surg Oncol. 2006;13:1123-9. (Pubitemid 44337972)
5. Beasley GM, Caudle A, Petersen RP, et al. A multi-institutional experience of isolated limb infusion: defining response and toxicity in the U.S. J Am Coll Surg. 2009;208:706-15.
6. Santillan AA, Delman KA, Beasley GM, et al. Predictive factors of regional toxicity and serum creatine phosphokinase levels after isolated limb infusion for melanoma: a multi-institutional analysis. Ann Surg Oncol. 2009;16:2570-8.
7. Wieberdink J, Benckhuysen C, Braat RP, et al. Dosimetry in isolated perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol. 1982;18:905-10. (Pubitemid 13147887)
8. Huismans AE, Kroon HM, Kam PC, Thompson JF. Does increased experience with isolated limb infusion for advanced limb melanoma influence outcome? A comparison of two treatment periods at a single institution. Ann Surg Oncol. 2011:1877-83.
9. Noorda EM, van Kreij RH, Vrouenraets BC, et al. The healthrelated quality of life of long-term survivors of melanoma treated with isolated limb perfusion. Eur J Surg Oncol. 2007;33:776-82. (Pubitemid 47029660)
10. Vrouenraets BC, in't Veld GJ, Nieweg OE, et al. Long-term functional morbidity after mild hyperthermic isolated limb perfusion with melphalan. Eur J Surg Oncol. 1999;25:503-8.
11. Van Geel AN, van Wijk J, Wieberdink J. Functional morbidity after regional isolated perfusion of the limb for melanoma. Cancer. 1989;63:1092-6. (Pubitemid 19074737)
12. Knorr C, Melling N, Goehl J, et al. Long-term functional outcome after hyperthermic isolated limb perfusion (HILP). Int J Hyperthermia. 2008;24:409-14.
13. Olieman AF, Schraffordt Koops H, Geertzen JH, et al. Functional morbidity of hyperthermic isolated regional perfusion of the extremities. Ann Surg Oncol. 1994;1:382-8.